Trial Condition(s):

Multiple Sclerosis

BENEFIT Extension Study

Bayer Identifier:

91713

ClinicalTrials.gov Identifier:

NCT00544037

EudraCT Number:

Not Available

Study Completed

Trial Purpose

To assess the long-term effects of early therapeutic intervention, i.e. within two years following a first clinical demyelinating event suggestive of MS.

Inclusion Criteria
- All patients randomized and treated at least once in study 304747
Exclusion Criteria
- Medical, psychiatric or other conditions that compromise the patient's ability to understand the purpose of the study

Trial Summary

Enrollment Goal
283
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Betaseron (Interferon beta-1b, BAY86-5046)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Investigative Site

Many Locations, Canada

Status
Completed
 
Locations

Investigative Site

Many Locations, Switzerland

Status
Completed
 
Locations

Investigative Site

Many Locations, Hungary

Status
Completed
 
Locations

Investigative Site

Many Locations, Israel

Status
Completed
 
Locations

Investigative Site

Many Locations, Norway

Status
Completed
 
Locations

Investigative Site

Many Locations, Sweden

Status
Completed
 
Locations

Investigative Site

Many Locations, Austria

Status
Completed
 
Locations

Investigative Site

Many Locations, Belgium

Status
Completed
 
Locations

Investigative Site

Many Locations, Poland

Status
Completed
 
Locations

Investigative Site

Many Locations, Denmark

Status
Completed
 
Locations

Investigative Site

Many Locations, Slovenia

Status
Completed
 
Locations

Investigative Site

Many Locations, Czech Republic

Status
Completed
 
Locations

Investigative Site

Many Locations, Italy

Status
Completed
 
Locations

Investigative Site

Many Locations, Finland

Status
Completed
 
Locations

Investigative Site

Many Locations, Germany

Status
Completed
 
Locations

Investigative Site

Many Locations, France

Status
Completed
 
Locations

Investigative Site

Many Locations, Netherlands

Status
Terminated
 
Locations

Investigative Site

Many Locations, Spain

Status
Completed
 

Trial Design